Status:
COMPLETED
Peripheral KV7 Activation for Pain Relief
Lead Sponsor:
Stefan Heber
Conditions:
Pain
Eligibility:
All Genders
18-70 years
Phase:
EARLY_PHASE1
Brief Summary
The goal of this clinical trial is to learn if the drug Flupirtine can safely lower pain when used in tiny amounts directly in the skin. The study will test whether Flupirtine works by activating spec...
Detailed Description
This randomized, placebo-controlled crossover clinical trial investigates whether a very small (microdose) amount of the drug Flupirtine, when injected directly into the skin, can reduce pain caused b...
Eligibility Criteria
Inclusion
- Age between 18 and 70 years
- Full legal capacity To ensure an equal number of each sex in the study population, only volunteers of one sex will be included as soon as the number of subjects with the other sex has reached half of the calculated sample size.
Exclusion
- Participant of another study, ongoing or within the last 4 weeks
- Medication intake (except contraception) or drug abuse
- Female subjects: Positive pregnancy test or breastfeeding
- Body temperature above 38°C, diagnostically verified
- Known allergic diseases, in particular asthmatic disorders and skin diseases
- Sensory deficit, skin disease or hematoma of unknown origin in examination of the test site
Key Trial Info
Start Date :
May 8 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2025
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06971250
Start Date
May 8 2025
End Date
May 28 2025
Last Update
June 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, Austria, 1090